Clinical Trials
18 trialsNCT01130025 2025-02-24
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
LEO Pharma
Phase 3 Completed
NCT01583218 2023-08-07
APEX
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT05461807 2022-10-26
H2H-OSCAR-US
Bayer
Completed
NCT02921802 2022-06-14
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Celgene
Completed
NCT02922543 2022-06-14
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
Celgene
Completed
NCT03965741 2021-11-30
PRACTISE
Bayer
Completed
NCT03099031 2019-12-16
PREDICARE
LEO Pharma
Completed
NCT02555878 2019-09-12
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
Janssen Research & Development, LLC
Phase 3 Completed
NCT00952380 2019-04-16
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
Pfizer
Phase 2 Completed
NCT02073682 2019-03-06
Cancer Venous Thromboembolism (VTE)
Daiichi Sankyo
Phase 3 Completed
NCT03214172 2018-09-06
Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
Bayer
Completed
NCT01803022 2018-02-05
Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer
LEO Pharma
Completed
NCT01444612 2017-05-16
Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery
GlaxoSmithKline
Completed
NCT01325558 2016-07-15
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
Altor BioScience
Phase 1 Completed
NCT01362933 2015-03-06
CARMEN
Floralis
Completed
NCT00694382 2013-01-23
SAVE-ONCO
Sanofi
Phase 3 Completed
NCT00219973 2010-04-28
CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)
Rovi Pharmaceuticals Laboratories
Phase 3 Completed
NCT00723216 2010-04-05
Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery
Sanofi
Phase 3 Completed